Summary of opinion: Vueway,Gadopiclenol, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Vueway,Gadopiclenol, 12/10/2023, Positive
Summary of opinion: Albrioza,sodium phenylbutyrate,Ursodoxicoltaurine, 12/10/2023, Negative
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Albrioza,sodium phenylbutyrate,Ursodoxicoltaurine, 12/10/2023, Negative
Summary of opinion: Veoza,fezolinetant, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Veoza,fezolinetant, 12/10/2023, Positive
Summary of opinion: Imfinzi,durvalumab, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Imfinzi,durvalumab, 12/10/2023, Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023
Summary of opinion: Keytruda,pembrolizumab, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Keytruda,pembrolizumab, 12/10/2023, Positive
Summary of opinion: Rubraca,rucaparib, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Rubraca,rucaparib, 12/10/2023, Positive
Summary of opinion: Jemperli,dostarlimab, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Jemperli,dostarlimab, 12/10/2023, Positive
Summary of opinion: Elucirem,Gadopiclenol, 12/10/2023, Positive
Submitted by Anonymous (not verified) on 13 October 2023 - 11:00
Summary of opinion: Elucirem,Gadopiclenol, 12/10/2023, Positive
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications, Date of authorisation: 25/08/2022, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2023 - 10:24
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications, Date of authorisation: 25/08/2022, Revision: 4, Status: Authorised